Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of <i>BRCA1/2</i> mutation status.

Ann Transl Med · 2020 · PMC7576024 · PMID 33241032

Europe PMC DOI

hedged sentence

0.5100

closest p · 10.2× alpha

0.5100

boldest claim

The sentences

showed a trendP=0.51not close (p > 0.1)

Patients with BRCA1/2 mutations also showed a trend towards worse survival outcomes compared to non-carriers after adjustment for systemic therapy (HR =1.49; 95% CI: 0.45–4.97; P=0.51) and surgical management of the breast (HR =1.63; 95% CI: 0.48–5.54; P=0.43), although this did not reach the level of significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.